Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long ...

Your university course is much more than lectures, seminars, and readings. It’s also a soundtrack. Whether your course is part of the elite group of STEM or the much cooler humanities group, it can be ...

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol ...

Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as ...

The arduous coursework and academic pressure, combined with the warnings from seniors and alumni about the state of the job ...

Rachel Reeves is expected to switch her tax-raising attentions to savers, asset owners and freezing thresholds after dropping ...

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol ...

Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30404 EPS, expectations were $-0.04. Operator ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third ...

Explore rising inflation, Fed rate cuts, and tight credit spreads. Discover why precious metals are soaring and how resource ...

SAN MATEO, Calif., Nov. 12, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative ...